 |
|
|
|
|
|
|
|
|
|
|
|
1 to 15 of 15 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Agadjanyan M. on NEWS: Bapineuzumab Phase 3: Target Engagement, But No Benefit, Immunotherapy is a potentially powerful strategy for reducing the level of Aβ in the brain.... 21 Sep 2012.
|
|
|
 |
|
|
Agadjanyan M. on NEWS: Smuggling Antibodies to BACE Across the Blood-Brain Barrier, Delivery of antibodies into the brain using bispecific antibodies is a very interesting... 5 Jun 2011.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Lambracht-Washington D. et al., 2009, I'd like to thank Dr. Lambracht-Washington et al. for their reply and respond to a few points.
... 11 Nov 2009.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Lambracht-Washington D. et al., 2009, I’d like to offer for the field’s collective consideration my view that this manuscript is... 5 Nov 2009.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Thakker DR. et al., 2009, It is well known that at first anti-Aβ vaccination (active and passive) in mouse models of AD... 4 Mar 2009.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Movsesyan N. et al., 2008, Reply to comments above and on related 29 May 2008.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Pride M. et al., 2008, This comment concerns both this paper (Pride et al., 2008) and the recent news about the... 7 May 2008.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Head E. et al., 2008, I'd like to discuss the similarities between data generated in APP/Tg mice vaccinated with an AD... 11 Apr 2008.
|
|
|
|
|
|
Agadjanyan M. on SITE POLL: Does Abeta have a normal function? Must we understand it in order to conquer AD?, To use anti-Aβ immunotherapy and other therapeutic strategies targeting Aβ, we must understand... 30 Jan 2007.
|
|
|
|
|
|
Agadjanyan M. on NEWS: Immunotherapy Update: Toward Patches and Creams, In this interesting paper, Nikolic and colleagues examined the efficacy of transcutaneous... 30 Jan 2007.
|
|
|
|
|
|
Agadjanyan M. on NEWS: Aβ Star is Born? Memory Loss in APP Mice Blamed on Oligomer, Normally, soluble Aβ molecule (39-43 amino acids) undergoes conformational changes in disease... 21 Jun 2006.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Okura Y. et al., 2006, The PNAS paper by Okura et al. describes results regarding a DNA-based Alzheimer disease... 15 Jun 2006.
|
|
|
|
|
|
Agadjanyan M. on PAPER: Masliah E. et al., 2005, α-synuclein is a soluble protein that is highly enriched in the presynaptic terminals of neurons... 17 Jun 2005.
|
|
|
|
|
|
Agadjanyan M. on NEWS: Immunotherapy Protects against Synaptic Effects of Soluble Amyloid-β Oligomers, Recently, Cleary et al. reported that conditioned medium from a 7PA2 cell line that stably... 3 May 2005.
|
|
|
|
|
|
Agadjanyan M. on NEWS: Pilot Study Shows Promise of Passive Immunotherapy, Dr. Norman Relkin and colleagues reported about the use of intravenous immunoglobulin (IVIG) in... 29 Apr 2005.
|
|
|
|
|
|
|
1 to 15 of 15 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
